TGTX TG Therapeutics Inc.

13.7
-0.33  -2%
Previous Close 14.03
Open 14.53
Price To Book -52.69
Market Cap 1,363,991,646
Shares 99,561,434
Volume 2,988,260
Short Ratio
Av. Daily Volume 2,275,390
Stock charts supplied by TradingView

NewsSee all news

  1. TG Therapeutics Initiates Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration for Umbralisib as a Treatment for Patients with Previously Treated Marginal Zone Lymphoma or Follicular Lymphoma

    TG received guidance from the FDA allowing submission of a single NDA for Marginal Zone Lymphoma (MZL) and Follicular Lymphoma indications Completion of rolling submission for the MZL/FL NDA expected in 1H20 NEW YORK,

  2. TG Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference

    NEW YORK, Jan. 10, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX) today announced that Michael S. Weiss, the Company's Executive Chairman and Chief Executive Officer, will present at the 38th Annual J.P.

  3. TG Therapeutics Announces $50.0 Million Registered Direct Public Offering of Common Stock to a Single Institutional Investor

    NEW YORK, Dec. 23, 2019 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX), today announced it has entered into a definitive agreement to sell approximately 5.4 million shares of registered common stock of the

  4. TG Therapeutics Announces Phase I Data Presentation for TG-1701, a Once-Daily BTK Inhibitor, as a Single Agent and in Triple Combination with Ublituximab and Umbralisib (U2), at the 61st American Society of Hematology Annual Meeting and Exposition

    Proprietary triplet of U2 plus TG-1701 (BTK inhibitor) induced 86% ORR (6 of 7) in patients with relapsed/refractory NHL and CLL at the lowest dose of TG-1701 tested Single agent TG-1701 induced responses at multiple

  5. TG Therapeutics Announces Oral Presentation of Umbralisib, Ublituximab and Venetoclax Triple Combination Phase I/II Data in Relapsed/Refractory CLL at the 61st American Society of Hematology Annual Meeting and Exposition

    100% overall response rate (ORR) in relapsed/refractory CLL patients treated with U2 (umbralisib + ublituximab) plus venetoclax at cycle 7 (n=13) 100% of patients (n=9) achieved undetectable MRD in the peripheral

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 initiation announced November 27, 2017.
TGR-1202 (umbralisib) plus obinutuzumab
Relapsing or refractory Follicular Lymphoma
Phase 2 long term follow up data presented at ECTRIMS, September 12, 2019.
TG-1101 (ublituximab)
Relapsing forms of Multiple Sclerosis (RMS)
Phase 3 data due in the middle to 2H 2020.
TG-1101 - ULTIMATE II
Multiple Sclerosis
Phase 1/2 updated data noted 91% ORR for CLL patients; 38% for Richter’s transformation.
Umbralisib (TGR-1202) + Pembrolizumab + Ublituximab (TG-1101)
Relapsed or refractory Chronic Lymphocytic Leukemia (CLL)
Phase 3 data due in the middle to 2H 2020.
TG-1101 - ULTIMATE I
Multiple Sclerosis
Rolling NDA has commenced - noted January 16, 2020. To be completed 1H 2020.
Umbralisib
Marginal zone lymphoma (MZL) and follicular lymphoma (FL)
Phase 3 trial met primary endpoint - March 6, 2017. Data presented at ASCO 2017.
TG-1101 and IMBRUVICA (GENUINE trial)
Chronic Lymphocytic Leukemia (CLL) cancer
Phase 3 PFS data due early 2020.
TG-1101 and TGR-1202 - UNITY-CLL study
Chronic Lymphocytic Leukemia (CLL) and non-Hodgkin's Lymphoma (NHL)
Phase 1 updated data released at EHA June 2018. 2 patients (9%) achieved a durable complete remission.
TGR-1202
Myelofibrosis
Phase 1 trial initiation announced February 26, 2019.
TG-1801
Relapsed or Refractory B-cell Lymphoma
Phase 1/2 data presented at ASH December 8, 2019 noted 100% ORR (9/9) including 44% CR after cycle 12 for the combination.
Umbralisib + Ublituximab + Venetoclax
Chronic Lymphocytic Leukemia
Phase 1 data presented at ASH December 9, 2019. ORR 86%.
TG-1701
Non Hodgkin Lymphoma / Chronic Lymphocytic Leukemia

Latest News

  1. TG Therapeutics Initiates Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration for Umbralisib as a Treatment for Patients with Previously Treated Marginal Zone Lymphoma or Follicular Lymphoma

    TG received guidance from the FDA allowing submission of a single NDA for Marginal Zone Lymphoma (MZL) and Follicular Lymphoma indications Completion of rolling submission for the MZL/FL NDA expected in 1H20 NEW YORK,

  2. TG Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference

    NEW YORK, Jan. 10, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX) today announced that Michael S. Weiss, the Company's Executive Chairman and Chief Executive Officer, will present at the 38th Annual J.P.

  3. TG Therapeutics Announces $50.0 Million Registered Direct Public Offering of Common Stock to a Single Institutional Investor

    NEW YORK, Dec. 23, 2019 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX), today announced it has entered into a definitive agreement to sell approximately 5.4 million shares of registered common stock of the

  4. TG Therapeutics Announces Phase I Data Presentation for TG-1701, a Once-Daily BTK Inhibitor, as a Single Agent and in Triple Combination with Ublituximab and Umbralisib (U2), at the 61st American Society of Hematology Annual Meeting and Exposition

    Proprietary triplet of U2 plus TG-1701 (BTK inhibitor) induced 86% ORR (6 of 7) in patients with relapsed/refractory NHL and CLL at the lowest dose of TG-1701 tested Single agent TG-1701 induced responses at multiple

  5. TG Therapeutics Announces Oral Presentation of Umbralisib, Ublituximab and Venetoclax Triple Combination Phase I/II Data in Relapsed/Refractory CLL at the 61st American Society of Hematology Annual Meeting and Exposition

    100% overall response rate (ORR) in relapsed/refractory CLL patients treated with U2 (umbralisib + ublituximab) plus venetoclax at cycle 7 (n=13) 100% of patients (n=9) achieved undetectable MRD in the peripheral

  6. TG Therapeutics Recaps Schedule of Triple Therapy Data Presentations at the Upcoming 61st American Society of Hematology Annual Meeting and Exposition

    NEW YORK, Dec. 06, 2019 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX), today recapped the schedule of triple therapy data presentations, at the upcoming 61st American Society of Hematology (ASH) annual

  7. TG Therapeutics to Present at the Jefferies London Healthcare Conference

    NEW YORK, Nov. 18, 2019 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX), today announced that Michael S. Weiss, the Company's Executive Chairman and Chief Executive Officer, will present at the Jefferies London

  8. TG Therapeutics Provides Business Update and Reports Third Quarter 2019 Financial Results

    NEW YORK, Nov. 12, 2019 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX) today announced its financial results for the third quarter ended September 30, 2019 and recent company developments. Michael S. Weiss,

  9. TG Therapeutics to Host Conference Call on Third Quarter 2019 Financial Results and Business Update

    NEW YORK, Nov. 08, 2019 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX), today announced that a conference call will be held, Tuesday, November 12, 2019 at 8:30 AM ET to discuss results for the third quarter of

  10. TG Therapeutics Announces Triple Combination Data Presentations at the Upcoming 61st American Society of Hematology Annual Meeting and Exposition

    100% overall response rate (ORR) in relapsed/refractory CLL patients (n=9) treated with U2 (umbralisib + ublituximab) plus venetoclax, with all patients at 12 months achieving MRD negativity (n=5) Proprietary triplet of

  11. TG Therapeutics Announces Final Long-Term Results from the Phase 3 GENUINE Study Demonstrated that Ublituximab in Combination with Ibrutinib Improved Progression-Free Survival in Patients with High-Risk Relapsed/Refractory Chronic Lymphocytic Leukemia as Compared to Ibrutinib Monotherapy

    Combination was well tolerated with no new safety signals identified with median follow-up of >4 years GENUINE met its primary endpoint of improved overall response rate, as previously reported TG plans to

  12. TG Therapeutics to Present at the 2019 Cantor Global Healthcare Conference

    NEW YORK, Oct. 02, 2019 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX), today announced that Michael S. Weiss, the Company's Executive Chairman and Chief Executive Officer, will participate in a fireside chat

  13. TG Therapeutics Announces Publication of Clinical Data from the Phase I/Ib Combination Trial of Ublituximab and Umbralisib ("U2") in Blood

    U2 combination was generally well-tolerated with relatively low rates of immune-mediated toxicities Combination treatment resulted in median progression free survival (PFS) of ~28 months in relapsed/refractory chronic

  14. TG Therapeutics Announces Data Presentations at the XVIII International Workshop on Chronic Lymphocytic Leukemia (iwCLL)

    Phase 2 study of umbralisib monotherapy in BTK/PI3K-delta intolerant CLL reports an estimated median progression-free survival (PFS) of 23.5 months (n=50) with 58% of patients on umbralisib longer than their prior kinase

  15. TG Therapeutics to Present at the Ladenburg Thalmann Healthcare Conference

    NEW YORK, Sept. 20, 2019 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX), today announced that Michael S. Weiss, the Company's Executive Chairman and Chief Executive Officer, will present at the Ladenburg

  16. TG Therapeutics Presents Data for Ublituximab at the 35th Annual Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)

    NEW YORK, Sept. 12, 2019 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX), today presented the first look at the ULTIMATE I & II Phase 3 trial design and demographic data and updated Phase 2 extension trial

  17. TG Therapeutics Announces Data Presentations at the Upcoming 35th Annual Congress of ECTRIMS

    NEW YORK, Aug. 29, 2019 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX), today announced that abstracts featuring ublituximab, the Company's novel, glycoengineered anti-CD20 monoclonal antibody, in relapsing

  18. TG Therapeutics Mourns the Loss of Board Member, Mark Schoenebaum, MD

    NEW YORK, Aug. 26, 2019 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX) announced with great sadness the passing of longtime Board Member, Mark Schoenebaum, MD. "Everyone at TG is incredibly saddened by